EDGAR·FLOW

ImmunityBio, Inc. — Form 8-K

Filed November 9, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
ImmunityBio announced that ANKTIVA (nogapendekin alfa inbakicept-pmln) plus BCG met its primary efficacy endpoint in the randomized QUILT-2.005 registrational trial of 370 BCG-naive non-muscle invasive bladder cancer (NMIBC) patients. The chemotherapy-free combination showed statistically significant improvement over BCG alone in carcinoma in situ patients; safety profile matched BCG alone with no treatment-related deaths. The company plans to submit a supplemental Biologics License Application (sBLA) to the FDA by year-end 2026 for this earlier-stage patient population, potentially expanding ANKTIVA's current indication (BCG-unresponsive NMIBC, approved April 2024).
Why this rating

Positive Phase 3 registration trial success in earlier-stage indication meaningfully expands addressable market; potential new indication could substantially increase ANKTIVA revenues. Material to $690M company but regulatory approval uncertain; meaningful fraction of pipeline value.

Tradability signal
NO TRADE

No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$9.00 ▲ 28.11%
at our read · unknown
$7.03
+10 min · unknown
$6.71 ▼ 4.48%
+30 min · unknown
$6.70 ▼ 4.67%
+1 hr · unknown
$7.04 ▲ 0.14%
+4 hrs · unknown
$7.20 ▲ 2.49%

The stock had already moved -21.94% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ IBRX · stock on Yahoo Finance ↗

See more from November 9, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.